Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer
暂无分享,去创建一个
J. Verweij | M. Polée | A. van der Gaast | G. Stoter | P. Siersema | H. Tilanus | F. Eskens | M. van der Burg | A. Gaast | M. Burg | T. Splinter | M. Polee | PD Siersema | HW Tilanus
[1] R. Heelan,et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. , 2000, Cancer journal.
[2] Blot Wj,et al. The changing epidemiology of esophageal cancer. , 1999, Seminars in oncology.
[3] G. Schwartz,et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] P. Siersema,et al. Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer , 1999, British Journal of Cancer.
[5] D. Kerr,et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. , 1999, The American journal of pathology.
[6] A. Lindgren,et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.
[7] J. Ajani,et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. , 1998, The New England journal of medicine.
[8] W. Schmiegel,et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. , 1998, British Journal of Cancer.
[9] J. Ajani,et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Bains,et al. A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report. , 1997, Seminars in oncology.
[11] L. Collette,et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. , 1997, European journal of cancer.
[12] C. H. Spiridonidis,et al. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma , 1996, Cancer.
[13] A. van der Gaast,et al. Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. , 1996, British Journal of Cancer.
[14] J. Silverstein,et al. A 15-year review of esophagectomy for carcinoma of the esophagus and cardia. , 1995, Archives of surgery.
[15] J B Vermorken,et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Ajani,et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. , 1994, Journal of the National Cancer Institute.
[17] J. Cooper,et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.
[18] M. Bains,et al. Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Csendes,et al. [Chemotherapy of esophageal cancer]. , 1984, Revista medica de Chile.
[20] M. Palmer,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1982, British Journal of Cancer.
[21] M. J. van den Bent,et al. Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration. , 1995, European journal of cancer.
[22] R. D. Hunter,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1980 .